Bayer Bets $2.45 Billion on Perfuse Eye Drug as Eylea Pressure Builds
Bayer AG will acquire Perfuse Therapeutics Inc. for up to $2.45 billion, including $300 million upfront and the rest tied to milestones. The deal gives Bayer full rights to PER-001, an eye drug in Phase II trials for glaucoma and diabetic retinopathy. Eylea, Bayer’s top-selling eye drug, saw sales fall 5.9% in 2025 due to generic competition. Analysts reacted cautiously to the acquisition.